Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cellectar Biosciences Inc | CLRB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.02 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.02 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.33 - 4.45 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.02 | USD |
Cellectar Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 30.45M | - | 0 | -37.98M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cellectar Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLRB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.03 | 3.2793 | 2.942 | 3.08 | 860,046 | -0.01 | -0.33% |
| 1 Month | 4.09 | 4.1499 | 2.942 | 3.48 | 936,241 | -1.07 | -26.16% |
| 3 Months | 3.88 | 4.45 | 2.942 | 3.66 | 1,030,036 | -0.86 | -22.16% |
| 6 Months | 2.47 | 4.45 | 1.87 | 3.42 | 1,142,555 | 0.55 | 22.27% |
| 1 Year | 1.50 | 4.45 | 1.33 | 3.19 | 745,335 | 1.52 | 101.33% |
| 3 Years | 1.64 | 6.7568 | 0.337 | 2.28 | 431,804 | 1.38 | 84.15% |
| 5 Years | 2.40 | 6.7568 | 0.337 | 2.08 | 559,656 | 0.62 | 25.83% |
Cellectar Biosciences Description
| Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. |
